Have a personal or library account? Click to login
Sarcopenic obesity in cancer Cover
Open Access
|Feb 2024

Figures & Tables

FIGURE 1.

Main pathophysiological mechanisms in cancer patients with sarcopenic obesity. Body composition (low skeletal muscle mass and strength, increase in fat mass), inflammation, insulin resistance, myosteatosis, myokine dysregulation, and oxidative stress in sarcopenic obese cancer patients significantly induce muscle proteolysis, leading to muscle wasting and dysfunction and premature mortality.
Main pathophysiological mechanisms in cancer patients with sarcopenic obesity. Body composition (low skeletal muscle mass and strength, increase in fat mass), inflammation, insulin resistance, myosteatosis, myokine dysregulation, and oxidative stress in sarcopenic obese cancer patients significantly induce muscle proteolysis, leading to muscle wasting and dysfunction and premature mortality.

Selected criteria to identify sarcopenic obesity_ Altered skeletal muscle function parameters considering muscle strength and physical performance and altered body composition parameters should be present to assess sarcopenic obesity

SCREENINGDIAGNOSISSTAGES
High BMI and WC (based on ethnic cut-points)Altered skeletal muscle strength (HGS, chair stand test)STAGE 1: Without complications
Surrogate markers of sarcopenia: (clinical symptoms or validated questionaries’ e.g. SARC-F)Altered body composition (increased FM, decrease MM)STAGE 2: One or more complications attributable to sarcopenic obesity
DOI: https://doi.org/10.2478/raon-2024-0011 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 1 - 8
Submitted on: Nov 2, 2023
Accepted on: Dec 4, 2023
Published on: Feb 21, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2024 Mihaela Jurdana, Maja Cemazar, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.